Ein GMP-konformes Verfahren zur Erzeugung genmodifizierter T-Zellen

Overview

This protocol describes a simplified and GMP compliant process of transducing human primary T-cells with a gene of interest. This method is designed to be cost-effective and avoids the use of expensive closed system manufacturing platforms.

Key Study Components

Area of Science

• Gene therapy
• Cellular transduction
• Immunotherapy

Background

• Transduction of T-cells is crucial for developing gene-modified cell therapies.
• CAR T-cells represent a significant advancement in treating hematologic malignancies.
• Current methods often rely on costly manufacturing systems.
• GMP compliance is essential for clinical applications.

Purpose of Study

• To provide a cost-effective method for T-cell transduction.
• To ensure compliance with GMP standards.
• To facilitate the generation of gene-modified therapies.

Methods Used

• Isolation of PBMC from donor blood via leukapheresis.
• Polysaccharide-based density gradient centrifugation.
• Maintaining a reagent to sample ratio of 1:2.
• Washing cells with PBS by centrifugation.

Main Results

• The protocol allows for efficient isolation of PBMCs.
• Demonstrates compliance with GMP standards.
• Provides a foundation for developing CAR T-cell therapies.
• Cost-effective compared to existing methods.

Conclusions

• This method can enhance the accessibility of gene-modified therapies.
• It addresses the need for cost-effective solutions in cell therapy.
• Future applications could significantly impact hematologic cancer treatment.

Frequently Asked Questions